 BOSTON, Aug. 03, 2022 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq: RYTM, a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor MC4R pathway diseases, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 12:30 p.m. ET in Boston, MA. 